Laetrile-marketer sentenced
This article was originally published in The Tan Sheet
Executive Summary
Christian Brothers Contracting Corp. President Jason Vale was sentenced June 18 to 63 months in prison and three years of supervised release for selling Laetrile, a bogus cancer cure, the U.S. District Court of the Eastern District of N.Y. ruled. Laetrile, also known as amygdalin, vitamin B-17 and "apricot pits," is "a highly toxic product that has not shown any effect on treating cancer," FDA says. Vale was convicted last July of three counts of criminal contempt for violating a 2000 court order to cease sale and promotion of Laetrile (1"The Tan Sheet" July 28, 2003, In Brief)...
You may also be interested in...
Laetrile marketer in contempt
Jason Vale, president of Christian Brothers Contracting, was convicted July21 of three counts of criminal contempt in violation of Title 18 by a federal jury in Brooklyn, New York, FDA announces July 24. A November 2000 court order directed Vale to terminate sale, promotion of Laetrile (amygdalin) (1"The Tan Sheet" Nov. 20, 2000, In Brief). Vale continued to sell the product, touting it as a cure for cancer. FDA notes there is no data supporting the cancer claims and the substance breaks down into cyanide gas once inside the body...
EU Orphan Drug Law Reform Will See Innovation Drop By 12%, Industry Warns
The European Commission’s proposals to overhaul the EU pharma legislation, which will see some orphan drug incentives cut, would cause a “significant dip in innovation,” according to number crunching from pharma industry association EFPIA.
BioFactura Completes Phase I For Late-To-Market Stelara Biosimilar
BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.